BrainEver
Last verified 2026-05-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $38.8Mattributed |
|---|---|
| Latest round | seed, $35.6M, 2025-07-01attributed |
| Founded | 2018 |
| Headquarters | Paris, France |
| Industry | biotech |
| Stage | series-b+ |
| Website | brainever.com |
Clinical-stage biotech developing homeoprotein-based therapies for ALS, Parkinson's and retinal disease. Built for patients with major neurodegenerative diseases lacking disease-modifying treatments. Lead candidate BREN02 (Engrailed 1) leverages founder Alain Prochiantz's discovery that developmental homeoproteins remain active throughout life.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-07-01 | seed | $35.6M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Seed, $35.6M | attributed | sifted named as publisher. No document URL on file. |
| Total raised $38.8M | attributed | sifted named as publisher. No document URL on file. |
| Company existence | self-reported | brainever.com, read 2026-05-02 |
| Description | self-reported | brainever.com, read 2026-05-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.